International Atomic Energy Agency
Department of Technical Cooperation
AndNuclear Medicine and Diagnostic Imaging Section
Division of Human Health
TN-RAS6083-1702276

IAEA/RCA Regional Training Course on Theragnostics andDementias
December 4-8, 2017
Osaka University Graduate School of Medicine,Osaka, Japan

Local Course Director
HATAZAWA, Jun
Osaka University Graduate School of Medicine
Department of Nuclear Medicine and Tracer Kinetics
565-0871 OsakaJapan
Tel: 81668793461
Fax: 81668793469
E-mail: hatazawa@tracer.med.osaka-u.ac.jp
IAEA TECHNICAL OFFICER
Mr. PASCUAL Thomas NB

PROGRAM

Monday 4 December 2017
AM: Cancer board hall (Oncology center 5F)
PM: Multimedia hall (CoMIT 1F)
10:00-10:30

Opening remarks
Pre-Course Evaluation

Pascual, Thomas(Technical Officer,IAEA)
Prof. Jun Hatazawa
Course Director

SESSION 1
Chair:
Dr. Frederik Giesel
University Hospital Heidelberg
Heidelberg, Germany
10:30-11:20

Introduction of theragnostics
ILO:
1. Review the concept and overview of theragnostics.

11:20-12:00

2. Understand the basic principle of BNCT.
Basic principle of theragnostics
ILO:
1. Recognize the significance of radiopharmaceuticals
used in theragnostics.

12:00-13:30

Integrate the concepts discussed in relation to bestpractices of theragnostics.
Lunch Break

13:30-14:20

Theragnostics: Neuroendocrine tumors

Prof. Jun Hatazawa
Osaka University,Osaka, Japan

Dr. Toru Shiga
Hokkaido University,
Sapporo, Japan

2.

ILO:
1. Recognize the radiopharmaceuticals used in PETand SPECT imaging for neuroendocrine tumors.
2. Understand the preparation and clinical regimen ofthe therapy using radiopharmaceuticals forneuroendocrine tumors.

End of session 1

Dr. Yuji Nakamoto,
Kyoto University,
Kyoto, Japan

SESSION 2
Chair:
Prof. Jun Hatazawa
Osaka University, Osaka, Japan
14:30-15:20

Brain perfusion SPECT for dementia
ILO:
1. Summarize the radiopharmaceuticals and typicalfindings of each dementia in brain perfusion
imaging.

Dr. Hiroshi Matsuda
National Center ofNeurology andPsychiatry, Tokyo,Japan

2. Recognize the typical pattern of dementia SPECT.
15:20-15:40

Coffee Break

15:40-16:20

Statistical Parametric Analysis in Nuclear Medicine
ILO:
1. Discuss the utilization of statistical image analysis indementia.

Dr. Hiroki Kato
Osaka University,
Osaka, Japan

2. Recognize the limitations of statistical image
analysis and importance of visual analysis.
16:20-17:00

Case presentation of Brain perfusion SPECTILO:
1. Discuss the key point of SPECT image
interpretation in dementia.

Prof. Eku
Shimosegawa
Osaka University,Osaka, Japan

2. Recognize the limitations of statistical image
analysis and importance of visual analysis.

End of session 2
17:30- Welcome Reception(Venue: Minerva, Second floor of Icho Kaikan)

Tuesday, 5 December 2017
AM: Multimedia hall (CoMIT 1F)
PM: Cancer board hall (Oncology center 5F)

SESSION 3
09:00-12:00

Parametric image analysis of brain images (includingsoftware practice):

Dr. Tadashi Watabe
Osaka University,
Osaka, JapanILO:
1. Describe appropriate ways of report writing inneurological cases with CT or MR interpretation.

Dr. Hiroki Kato
Osaka University,Osaka, Japan

2. Discuss the role of Brain Imaging using clinical cases
for image interpretation and its relevance in clinicalpractice.

End of session 3
12:00-13:00

Lunch BreakSESSION 4
Chair:
Dr. Pascual, Thomas (Technical Officer, IAEA)
13:00-13:30

Theragnostics: Neuroendocrine tumors (2)ILO:
1. Recognize the radiopharmaceuticals used indiagnosis and radionuclide therapy forneuroendocrine tumors.

13:30-14:202. Learn from the clinical case presentation ofDOTATOC imaging and Lu-Therapy.
Alzheimer’s Disease
ILO:
3. Understand the pathophysiology of Alzheimer’sdisease.
4. Discuss the role of nuclear medicine imaging inAlzheimer’s diseases.

Dr. Frederik Giesel(University Hospital
Heidelberg,Heidelberg,Germany)

Prof. Kazunari Ishii(Kinki University,Osaka, Japan)

14:20-15:10

PET and SPECT in Dementias (other than Alzheimer’sdisease)
ILO:
1. Understand the pathophysiology of dementias.

Dr. Takashi Kato
(National Center forGeriatrics andGerontology,Aichi, Japan)

2. Discuss the role of nuclear medicine imaging indementias.
15:10-15:30

Coffee Break

15:30-16:10

Case presentation of PET and SPECT about dementia (1)ILO:
1. Recognize the utility of PET and SPECT probes indementias.

Prof. Hiroshi
Toyama(Fujita HealthUniversity, Aichi,Japan)

2. Discuss the role of PET and SPECT imaging indementias.
16:10-16:50

Case presentation of PET and SPECT about dementia (2)ILO:
1. Understand the utility of nuclear medicine indementias.
2. Discuss the clinical relevance of nuclear medicine
imaging in dementias.

End of session 4

Prof. Toshimitsu
Momose(InternationalUniversity ofHealth and Welfare,Chiba, Japan)

Wednesday, 6 December 2017
AM: Multimedia hall (CoMIT 1F)

SESSION 5
09:00-12:00

Parametric image analysis of brain images (includingsoftware practice):
ILO:
1. Perform the statistical image analysis and write
report by yourself.
2. Discuss the role of Brain Imaging using clinicalcases for image interpretation and its relevance inclinical practiceEnd of session 5
12:00-14:00

Lunch Break

14:00-17:00

Technical visit

Dr. Hiroki Kato
Osaka University,Osaka, JapanThursday 7 December 2017
AM: Multimedia hall (CoMIT 1F)
PM: Meeting room B,C (Icho Kaikan 3F)

SESSION 6:
Chair:
Prof. Jun Hatazawa
Osaka University, Osaka, Japan
9:30-10:10

Theragnostics: Brain tumor
ILO:
1. Recognize the radiopharmaceuticals used in PETand SPECT imaging for brain tumor.

Dr. Frederik Giesel(University Hospital
Heidelberg,Heidelberg, Germany)

2. Understand the preparation and clinical regimen ofthe therapy using radiopharmaceuticals for braintumor.
10:10-10:50

Theragnostics: gastrointestinal tumors
ILO:
1. Recognize the radiopharmaceuticals used in PETand SPECT imaging for gastrointestinal tumors.

Prof. UkihideTateishi(Tokyo Medical andDental University,Tokyo, Japan)

2. Understand the preparation and clinical regimen of
the therapy using radiopharmaceuticals for
gastrointestinal tumors.
10:50-11:30

Theragnostics: lung cancer
ILO:
1. Recognize the radiopharmaceuticals used in PETand SPECT imaging for lung cancer.
2. Understand the preparation and clinical regimen of
the therapy using radiopharmaceuticals for lungcancer.

END OF SESSION 6
11:30-13:10

Lunch BreakDr. Hirofumi Fujii(National cancercenter, Tokyo, Japan)

SESSION 7:
Chair:
Dr. Frederik Giesel
University Hospital Heidelberg
Heidelberg, Germany
13:10-14:00

Theragnostics: thyroid
ILO:
1. Recognize the radiopharmaceuticals used in PETand SPECT imaging for thyroid.

Dr. Tatsuya Higashi(National Institute ofRadiological Sciences,Chiba, Japan)

2. Understand the preparation and clinical regimen of
the therapy using radiopharmaceuticals for thyroid.
14:00-14:40

Theragnostics: liver tumors (TACE and SIRT)
ILO:
1. Recognize the radiopharmaceuticals used in PETand SPECT imaging for liver tumors.

Dr. Keigo Osuga(Osaka University,Osaka, Japan)

2. Understand the preparation and clinical regimen of
the therapy using radiopharmaceuticals for livertumors.
14:40-15:00

Coffee Break

15:00-15:50

Theragnostics: malignant lymphoma
ILO:
1. Recognize the radiopharmaceuticals used in PETand SPECT imaging for malignant lymphoma.
2. Understand the preparation and clinical regimen of
the therapy using radiopharmaceuticals for malignantlymphoma.

END OF SESSION 7

Dr. Mitsuaki Tatsumi(Osaka University,Osaka, Japan)

Friday 8 December 2017
Multimedia hall (CoMIT 1F)

SESSION 8
CHAIR:
Dr. Tadashi Watabe
Osaka University, Osaka, Japan
09:00-09:40

Theragnostics: pediatric cancer
ILO:
1. Recognize the radiopharmaceuticals used in PET and
SPECT imaging for pediatric cancer.

Dr. Keiichiro
Yoshinaga(National Institute ofRadiologicalSciences, Chiba,Japan)

2. Understand the preparation and clinical regimen of
the therapy using radiopharmaceuticals for pediatriccancer.
09:40-10:30

Theragnostics: Prostate cancer
ILO:
1. Recognize the radiopharmaceuticals used in PET and
SPECT imaging for prostate cancer.

Dr. Frederik Giesel(University Hospital
Heidelberg,Heidelberg,Germany)

2. Understand the preparation and clinical regimen of
the therapy using radiopharmaceuticals for prostatecancer.
10:30-11:10

Future application of theragnostics

Prof. Seigo Kinuya(KanazawaUniversity,Kanazawa, Japan)

End of Session 8
11:10-12:00

Closing Remarks
Post course evaluation

Pascual, Thomas(Technical Officer,IAEA)
Prof. Jun Hatazawa
Course Director

-Map-